Triptan and Ergot Alkaloid Compositions for FMR1 Autism

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurological and developmental disorders such as autism and Fragile X Syndrome (FXS) are not widely effective, and there is a need for new therapeutic approaches that can address the specific symptoms and genetic mutations associated with these conditions.

Innovation Solution

The use of triptans or their derivatives, such as Sumatriptan, in combination with ergot alkaloids, to treat FMR1-mediated autism and FXS, targeting the underlying genetic mutations and symptoms like hyperarousal, social anxiety, and repetitive behaviors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for neurological and developmental disorders are used, then existing therapies can be administered, but they are not widely effective and do not adequately address specific symptoms and genetic mutations

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address specific symptoms and genetic mutations

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by modifying the pharmacological parameters of serotonergic activity through the use of triptans and ergot alkaloids. These compounds alter receptor binding characteristics and signal transduction pathways to achieve more effective treatment outcomes for FMR1-mediated autism and FXS symptoms, thereby improving treatment reliability while maintaining adaptability to specific symptom profiles

Inventive Principle:

Principle #35Parameter changes

2Reliability

If triptans or their derivatives are used in combination with ergot alkaloids, then behavioral and cognitive symptoms may be improved, but the complexity of treatment regimen increases

Engineering Contradiction:

Improveamelioration of phenotypesVSAvoidcomplexity of treatment regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies the merging principle by combining triptans or their derivatives with ergot alkaloids in a single treatment regimen. This combination approach targets multiple symptom domains simultaneously through synergistic pharmacological actions, improving phenotype amelioration while managing the complexity through integrated dosing strategies

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The combined treatment regimen exhibits multi-functionality by addressing diverse symptoms including hyperarousal, social anxiety, and repetitive behaviors through the coordinated action of triptans and ergot alkaloids. This universal approach allows a single treatment protocol to cover multiple symptom categories, thereby improving overall therapeutic effectiveness

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20230390243A1Compositions and Uses Thereof

Publication Date: 2023.12.07 PURPOSEFUL IKE

AI summary

The present invention relates to compositions for use in the treatment, management or amelioration of FMR1 mediated autism and Fragile X Syndrome (FXS), wherein the composition comprises one or more triptans or derivatives thereof. The invention also relates to one or more triptans or derivatives thereof and one or more ergot alkaloids, derivatives or mimetics thereof for use as medicaments for treating a range of autistic diseases and diseases having an autistic component.